live smallpox vaccine + OspaVir

This is a combination product consisting of a live smallpox vaccine (typically based on the vaccinia virus) and OspaVir. The live smallpox vaccine is an attenuated, replication-competent vaccinia virus preparation used to induce active immunity against smallpox and related orthopoxviruses such as mpox. It works by stimulating the immune system to recognize and respond to orthopoxvirus antigens, providing protection against infection[2][3][9]. OspaVir appears to be a trade or code name not widely recognized in major regulatory or scientific sources; however, based on context from similar combinations studied in the literature, it may refer to tecovirimat (also known as ST-246), an antiviral agent that inhibits the orthopoxvirus VP37 envelope-wrapping protein required for viral dissemination[4][5]. When used together, this combination aims both to provide immunization (via vaccination) and reduce adverse events or treat breakthrough infections (via antiviral action). The primary indications are prevention of smallpox and potentially mpox in high-risk populations.